FDA Panel Endorses Grail Galleri Cancer Blood Test — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA advisory panel endorsed Grail's Galleri blood test, which screens for multiple cancer types, concluding benefits outweigh risks
- Panel vote on safety was unanimous, 10-0, that there is reasonable assurance the Galleri test is safe
- Panel vote on effectiveness was much narrower at 6-4, with members split on whether there is reasonable assurance the test works
- Final benefit-vs-risk vote was 7-2 with one abstention, clearing the way for potential FDA approval though the FDA is not obliged to follow panel advice
- Grail, the biotech firm behind Galleri, designed the test as a multi-cancer screening tool — a single blood draw intended to flag signals across cancer types
Why it matters: The FDA frequently follows advisory panel recommendations, so this endorsement positions Grail to become one of the first companies with a commercially available multi-cancer screening blood test. But the 6-4 effectiveness split signals real clinical skepticism that could shape labeling, indicated-use restrictions, or post-market requirements if the FDA greenlights Galleri.
Ask SkimNews
